Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
229results about How to "Avoid weight gain" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Glucagon/glp-1 receptor co-agonists
InactiveUS20100190701A1High activityEnhanced biophysical stabilityPeptide/protein ingredientsAntibody mimetics/scaffoldsSolubilityCarboxylic acid
Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon / GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (K-RNRNNIA) and SEQ ID NO: 28 (KRNR).
Owner:INDIANA UNIV RES & TECH CORP
Sustained release formulation of naltrexone
ActiveUS20070281021A1Cause weight lossAvoid weight gainBiocideKetone active ingredientsSide effectCompound (substance)
A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.
Owner:OREXIGEN THERAPEUTICS INC
Acylated glucagon analogues
InactiveUS20120178670A1Avoid weight gainGood for weight lossPeptide/protein ingredientsAntipyreticDiabetes mellitusWeight gain prevention
The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Glucagon analogues
ActiveUS20140080757A1Avoid weight gainGood for weight lossBacteriaPeptide/protein ingredientsProviding materialObesity
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Sea Buckthorn compositions and associated methods
InactiveUS20050031718A1Weight controlLose weightBiocidePharmaceutical delivery mechanismBody weightToxicology
Compositions having an effective amount of a Sea Buckthorn extract and an inert carrier and methods of use therefor are disclosed and described. Such methods of use include may include controlling serum lipid concentrations in a subject, and controlling the body weight of a subject, among others.
Owner:PHARMANEX
Acylated glucagon analogues
ActiveUS20150111826A1Avoid weight gainGood for weight lossOrganic active ingredientsPeptide/protein ingredientsDiseaseReceptor
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Combination therapy
InactiveUS20090131447A1Mitigating effect adverse weight gain sideAvoid weight gainBiocideNervous disorderPharmaceutical drugDepressant
This invention is directed to the use of SCD-1 inhibitors of the formula (I): where x, y, V, W, G, J, L, M, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein, in combination with other drug therapies to treat adverse weight gain.
Owner:XENON PHARMACEUTICALS INC
Glucagon analogues
InactiveUS20130157935A1Effect on cholesterol levelAvoid weight gainPeptide/protein ingredientsMetabolism disorderWeight gain preventionProviding material
The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Glucagon analogues
ActiveUS20150111817A1Avoid weight gainGood for weight lossNervous disorderBacteriaProviding materialObesity
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Display device
InactiveCN101842826AImprove rigidityImprove retentionNon-linear opticsIdentification meansDisplay deviceMechanical engineering
Owner:SHARP KK
Methods for increasing cellular energy expenditure
InactiveUS20080031968A1Increased cellular energy expenditureImprove metabolic controlCompound screeningApoptosis detectionG protein-coupled receptorAgonist
The present invention is directed to methods of treating a human for a variety of conditions by administering an agonist of the G protein coupled receptor TGR5. In addition, the invention includes methods for determining whether a test compound is likely to be effective in treating one of these conditions by assaying it for its ability to raise intracellular iodothyronine deiodinase levels or for its ability to bind to and activate TGR5.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC +1
Glucagon analogues
ActiveUS9180169B2Avoid weight gainGood for weight lossPeptide/protein ingredientsMetabolism disorderProviding materialObesity
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Three-dimensional self-supported lithium-loving carrier-packaged metal lithium composite negative electrode and preparation method thereof
InactiveCN107799736AAvoid uneven electron/ion distributionFacilitates deposition/dissolutionMaterial nanotechnologyCell electrodesLithium electrodeCarbonization
The invention discloses a three-dimensional self-supported lithium-loving carrier-packaged metal lithium composite negative electrode and a preparation method thereof. The three-dimensional self-supported lithium-loving carrier-packaged metal lithium composite negative electrode comprises the following steps of 1) carbonizing melamine foam in an inertia atmosphere to obtain a nitrogen-rich lithium-loving three-dimensional self-supported carrier; and 2) packaging metal lithium in holes of the three-dimensional self-supported carrier to obtain the metal lithium composite negative electrode. Carbon sponge obtained by carbonization of melamine foam is used as a metal lithium carrier, and the metal lithium composite negative electrode has effects of guiding metal lithium to be uniformly deposited and preventing dendrite from being generated. Lithium-loving functional groups are uniformly arranged on the carrier, a lithium-loving coating layer is deposited on a hole surface of the carrier, the lithium-loving performance of the carrier is improved, the volume change of the metal lithium electrode during the circulation process is effectively buffered, moreover, the lithium-loving functional groups uniformly arranged on the three-dimensional carrier are used as active sites for metal lithium deposition, the nucleation over-potential is reduced, uniform nucleation of metal lithium can be effectively controlled, so that the dendrite generation is prevented.
Owner:SHANDONG UNIV
Acylated glucagon analogues
InactiveUS9156901B2High potencyHigh selectivityPeptide/protein ingredientsAntipyreticDiabetes mellitusWeight gain prevention
Owner:ZEALAND PHARM AS
Probiotic bacteria and regulation of fat storage
InactiveUS20100254956A1Reduced uptakeExtended shelf lifeMilk preparationBiocideBifidobacteriumBacteroides
The present invention provides methods for manufacturing heat treated products involving the use of probiotic bacteria, e.g. lactic acid bacteria and / or Bifidobacteria, cultures of such bacteria, supernatant from such cultures, and / or concentrates of such supernatant and / or fractions of such supernatant. The invention further provides heat treated products of such processes and their use for regulation of cellular uptake of fat and / or triglycerides and / or body weight management or weight reduction and / or redistribution of fat and / or reduction in visceral and / or abdominal fat deposition in a subject.
Owner:ARLA FOODS AMBA
Methods of preventing weight gain
ActiveUS20060073217A1Prevent and reduce weight gainImprove efficiencyBiocideMetabolism disorderHalf-lifeAgonist
Methods for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed.
Owner:OTOLANUM
Glucagon analogues
InactiveUS20160347813A1Avoid weight gainGood for weight lossPeptide/protein ingredientsMetabolism disorderBody weightWeight gain
The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain, and the treatment of obesity or excess body weight and associated conditions. The compounds may also be used to improve glycemic control and / or for the treatment of diabetes. The compounds may mediate their effect, inter alia, by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Acylated glucagon analogues
InactiveUS20160120951A1High potencyHigh selectivityPeptide/protein ingredientsAntipyreticDiabetes mellitusDisease
The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Acylated glucagon analogues
ActiveUS9896495B2Avoid weight gainGood for weight lossOrganic active ingredientsPeptide/protein ingredientsProviding materialObesity
Owner:ZEALAND PHARM AS
Glucagon analogues
InactiveUS9403894B2Effect on cholesterol levelAvoid weight gainPeptide/protein ingredientsMetabolism disorderProviding materialWeight gain prevention
The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the glucagon-like peptide-1 (GLP-1) receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Sustained release formulation of naltrexone
ActiveUS8916195B2Cause weight lossAvoid weight gainBiocideKetone active ingredientsSide effectSustained-Release Preparations
A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.
Owner:OREXIGEN THERAPEUTICS INC
Vehicle seat frame
A vehicle seat frame having high strength achieved without involving an increase in the weight of the seat frame. A back center frame (23) of a seatback frame (20) is hollow and has a rectangular pillar-like shape. A connection member (32) has a circular tube section (33) having a circular outer periphery, a ceiling section (34) projecting inward from axial one end of the circular tube section (33), and a flange section (35) projecting outward from the other axial end of the circular tube section (33). The ceiling section (34) of the connection member (32) is secured to the inner surface of one side plate section (23a) of the back center frame (23), that surface of the flange section (35) which is located on the circular tube section (33) side is secured to the outer surface of the other side plate section (23b) of the back center frame (23), and that surface of the flange section (35) which is located on the opposite side of the circular tube section (33) is connected to a bracket (14) with a recliner (30) in between.
Owner:AISIN SEIKI KK
Compositions and methods for managing weight
ActiveUS20140004215A1Promoting and managing weight lossMaintain weightBiocideNervous disorderPsychotropic AgentStimulant
The present disclosure provides Diels-Alder adducts of chalcone and prenylphenyl moieties capable of modulating the activity of cannabinoid receptors, and to oligomers of flavan-3-ol capable of modulating fat absorption and storage. Such Diels-Alder adducts of chalcone and prenylphenyl moieties or oligomers of flavan-3-ol can optionally be used in combination with other weight management agents, such as anorectic agents, a lipase inhibitors, other cannabinoid receptor modulators, psychotropic agents, insulin sensitizers, stimulants, or satiety agents, as well as to methods of use thereof such as treating or preventing weight gain or obesity, promoting weight loss, appetite suppression, modifying satiety, or the like.
Owner:UNIGEN
Method of using a green coffee bean extract to promote carnitine palmitoyltransferase activity
InactiveUS20110189313A1Improve securitySimple compositionCosmetic preparationsBiocideDiseaseAdditive ingredient
(Problems) To provide a highly safe dietetic composition originating in green coffee beans by which excellent dietetic effects can be obtained and which contributes to the prevention and treatment of life style-related diseases such as diabetes.(Means for Solving Problems) A dietetic composition characterized by comprising, as the active ingredient, a polar solvent extract of defatted green coffee beans. It is preferable that the above-described polar solvent extract is an extract obtained by using water-containing ethanol, still preferably water-containing ethanol having an ethanol concentration of from 40 to 90% (wt / wt). It is preferable that the above-described defatted green coffee beans are those obtained by extracting green coffee beans with N-hexane to thereby separate oily components therefrom. It is recommended to combine the above-described dietetic composition with one or more members selected from among salacia extract, evening primrose extract, sesamine and garcinia. This dietetic composition is usable as a material for foods, drinks, drugs, or skin preparations for external use.
Owner:ORIZA YUKA KK
Sea Buckthorn Compositions and Associated Methods
InactiveUS20060263459A1Weight controlLose weightBiocidePharmaceutical delivery mechanismBody weightToxicology
Compositions having an effective amount of a Sea Buckthorn extract and an inert carrier and methods of use therefor are disclosed and described. Such methods of use include may include controlling serum lipid concentrations in a subject, and controlling the body weight of a subject, among others.
Owner:PHARMANEX
Supercharger with electric motor
ActiveCN1912363ASuppresses the influence of loadabilityAvoid weight gainInternal combustion piston enginesGas turbine plantsImpellerCooling fluid
In a supercharger (10) with an electric motor in accordance with the present invention, the electric motor (20) is arranged at a position adjacent to a compressor impeller (6), a center housing (14) has a cooling fluid flow path (34) formed in such a manner as to surround the electric motor (20) and be adjacent to a diffuser portion (25). A first cooling structure portion (38) is formed at a position in the electric motor (20) side in the cooling fluid flow path (34), a second cooling structure portion(39) is formed at a position in the diffuser portion (25) side in the cooling fluid flow path (34). The electric motor (20) is cooled by the first cooling structure portion (38). The diffuser portion (25) is cooled by the second cooling structure portion (39).
Owner:IHI CORP
Glucagon analogues
ActiveUS9988429B2Avoid weight gainGood for weight lossNervous disorderPeptide/protein ingredientsProviding materialObesity
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Vehicle periphery alert device
ActiveCN103460264ALow costAvoid weight gainPedestrian/occupant safety arrangementAnti-collision systemsEngineeringBiological activation
Owner:TOYOTA JIDOSHA KK
Acylated glucagon analogues
ActiveUS20180141990A1Avoid weight gainGood for weight lossOrganic active ingredientsPeptide/protein ingredientsDiseaseReceptor
The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
Owner:ZEALAND PHARM AS
Vehicle seat frame
InactiveCN101778737AAvoid deformationAvoid weight gainMovable seatsBelt anchoring devicesBelt safetyCushion
A vehicle seat frame having high strength effectively achieved without involving an increase in the weight of the seat frame. The vehicle seat frame has a seat cushion frame (10) for supporting a seat cushion (90), a seatback frame (20) for supporting a seatback (91), a recliner (30) pivotably connecting the seatback (91) to the seat cushion (90) and adjusting the pivoting angle of the seatback (91), and a shoulder belt anchor (27) mounted on the seatback frame (20) and supporting one end of a shoulder belt. A back center frame (23) of the seatback frame (20) has outer peripheral sections (23a, 23b, 23c, 23d) having a hollow rectangular pillar shape and also has a reinforcement plate (23e) received in the outer peripheral sections (23a, 23b, 23c, 23d) and installed parallel to the direction of a load applied to the shoulder belt anchor (27) by the shoulder belt (51a).
Owner:AISIN SEIKI KK
Features
- R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
Why Patsnap Eureka
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com